TECHNOLOGY

The main technology of Metafines , called ‘ASCA101’ is related to new pharmacological composition for cancer treatment. ‘ASCA101’ is metabolic anti-cancer drug that has excellent therapeutic effect by disrupting the metabolic processes of working cancer cells in duplicate and complex ways through different mechanisms are acted in each cancer cell due to simultaneous uptake of different compounds to cancer cells. And also, ‘ASCA101’ is less susceptible to drug resistance, which can more effectively inhibit the effects of cancer cells such as proliferation, infiltration, and metastasis.

• ASCA101

• Inducing Cytotoxicity,
  Apoptosis with
  Cancer Cell
  Selectivity

  Low-Toxic Drug
  Repositioning NCE

  Inducing Cytotoxicity,
  Apoptosis with
  Cancer Cell
  Selectivity

  Anti-cancer Drug of
  complex mechanism
  (ATP depletion,
  ROS increase)

PIPELINE

Proceed Domestic and Global Clinical Trials sequentially → Aim to release New Drug in 2025

Pipelines		Indication	Discovery	Pre-Clinical	PhaseⅠ	PhaseⅡ	PhaseⅢ	NDA
Metabolic Anticancer Therapy	ASCA101(IntraVenous)	Solid Cancer	2021 3Q Domestic Phase I Entry The beginning of 2022 Clinical trial will be started in US
	ASCA101(New Formulation)
	MF02
Anticancer Combi Therapy	ASCA101 / MF02 + Existing Anticancer Drug	Refractory Cancer
Palliative Anticancer Therapy	MF03	Cancer Acidosis
	MF04	Cachexia

CEO GREETING

“ Meta(bolism) + Fines ”

Welcome to visit. MetaFines Corp. , as the company name suggests,
is a company that is researching and developing excellent anti-cancer
drugs using cancer metabolism (cancer metabolism drugs).